- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14,500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
- 03:00 PM CavinKare eyes Rs 100cr revenues from restaurant b...



Angel Broking has maintained its buy rating on Sun Pharma with price target of Rs 1273 in its February 02, 2009 report. "Sun Pharma’s 3QFY2009 numbers were below our expectations. The company posted Net Sales of Rs 918.3 crore, registering a yoy growth of 14.2%. For 3QFY2009, Net Profit came in at Rs 408.6 crore, up 28.4% yoy mainly driven by OPM expansion but was below our estimate of Rs 450 crore on account of lower contribution from Protonix. On the valuation front, at Rs 1,047, the stock is trading at 12.4x FY2009E and 14.8x FY2010E Earnings. We maintain a Buy on the stock, with a target price of Rs 1,273," says Angel Broking's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click on the attachment......
Attachments : Sun Pharma-RU3QFY2009-020209.pdf |
|
Stock Advice
|
|
|


Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO


-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14,500 at some point…'
- Mahindra Satyam restarts hirings, recalls bench
- Exit Suzlon Energy at Rs 83: Joshi

- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead

- SBI cuts deposit rates on slow credit, liquidity glut
- 'The Sensex will test 14,500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- 'India would've grown at 7% had monsoon not played truant'
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line





















